Search research articles
Contact Us
Filters
Showing results (121-130 of 141) with videos related to
Page
of 15
Sort By:
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2024
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 19, 2021
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study
S Hashemi, M F Fransen, A Niemeijer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2022
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Fenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Journal for Immunotherapy of Cancer
|
September 30, 2024
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Idris Bahce, Chris Dickhoff, Famke L Schneiders, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
J W T van der Wel, M Jebbink, D van den Broek, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 8, 2021
Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer
Merle I Ronden, Idris Bahce, Sayed M S Hashemi, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 141) with videos related to
Sort By:
Page
of 15
JTO Clinical and Research Reports
|
April 10, 2023
Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC
M Jebbink, A J de Langen, K Monkhorst, et al.
Journal for Immunotherapy of Cancer
|
February 1, 2024
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 19, 2021
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study
S Hashemi, M F Fransen, A Niemeijer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2022
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial
Fenneke Zwierenga, Bianca van Veggel, Lizza E L Hendriks, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2026
Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564]
Silvia Novello, David R Spigel, Jian Fang, et al.
ESMO Open
|
June 13, 2022
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis
U Dafni, R A Soo, S Peters, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial
Silvia Novello, Ying Cheng, David Spigel, et al.
Journal for Immunotherapy of Cancer
|
September 30, 2024
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
Idris Bahce, Chris Dickhoff, Famke L Schneiders, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
J W T van der Wel, M Jebbink, D van den Broek, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 8, 2021
Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer
Merle I Ronden, Idris Bahce, Sayed M S Hashemi, et al.
Page
of 15